Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Cystine stones

INTRODUCTION

Cystinuria is a genetic cause of kidney stones with an average prevalence of 1 in 7000 births [1]. Cystine stones are found in 1 to 2 percent of stone formers, although they represent a higher percentage of stones in children (about 5 percent) [2].

Cystinuria is part of the Rare Kidney Stone Consortium, an organization with international collaboration focused upon research and education aimed at improving care for these patients.

Cystinuria is a different disorder from cystinosis, which is characterized by intracellular cystine accumulation leading to the Fanconi syndrome and progressive renal failure. (See "Cystinosis".)

PATHOGENESIS, GENETICS, AND CLASSIFICATION

Cystine is a homodimer of the amino acid cysteine. Patients with cystinuria have impairment of renal cystine transport, with decreased proximal tubular reabsorption of filtered cystine resulting in increased urinary cystine excretion and cystine nephrolithiasis [3-5]. The cystine transporter also promotes the reabsorption of the other dibasic amino acids, including ornithine, arginine, and lysine, but these compounds are relatively soluble and an increase in their excretion does not lead to stones. Intestinal cystine transport is also diminished, but the result is of uncertain clinical significance.

Classification — Previously, cystinuria was classified according to the amount of cystine excreted by the parents of the affected child. In this phenotypic classification system, patients were classified as type I if their parents excreted normal amounts of cystine, and types II or III if parental cystine excretion was either greatly (II) or moderately (III) increased. However, with the identification of the genes responsible for this disorder (specifically, SLC3A1 and SLC7A9), a genotypic classification of cystinuria has been introduced [5-8]. Neither the genotypic nor the phenotypic classification appears to be relevant with respect to the clinical course in patients with cystinuria, as is discussed below. (See 'Genotype-phenotype correlation with stone risk' below.)

                                     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2014. | This topic last updated: Sep 11, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Chillarón J, Font-Llitjós M, Fort J, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010; 6:424.
  2. Stapleton FB. Childhood stones. Endocrinol Metab Clin North Am 2002; 31:1001.
  3. Palacin M, Goodyer P, et al. Cystinuria. In: The Metabolic and Molecular Basis of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.4909.
  4. Goodyer P. The molecular basis of cystinuria. Nephron Exp Nephrol 2004; 98:e45.
  5. Mattoo A, Goldfarb DS. Cystinuria. Semin Nephrol 2008; 28:181.
  6. Dello Strologo L, Pras E, Pontesilli C, et al. Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: a need for a new classification. J Am Soc Nephrol 2002; 13:2547.
  7. Leclerc D, Boutros M, Suh D, et al. SLC7A9 mutations in all three cystinuria subtypes. Kidney Int 2002; 62:1550.
  8. Chesney RW. Mutational analysis of patients with cystinuria detected by a genetic screening network: powerful tools in understanding the several forms of the disorder. Kidney Int 1998; 54:279.
  9. Feliubadaló L, Font M, Purroy J, et al. Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (bo,+AT) of rBAT. Nat Genet 1999; 23:52.
  10. Calonge MJ, Gasparini P, Chillarón J, et al. Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine. Nat Genet 1994; 6:420.
  11. Bisceglia L, Purroy J, Jiménez-Vidal M, et al. Cystinuria type I: identification of eight new mutations in SLC3A1. Kidney Int 2001; 59:1250.
  12. Schmidt C, Vester U, Wagner CA, et al. Significant contribution of genomic rearrangements in SLC3A1 and SLC7A9 to the etiology of cystinuria. Kidney Int 2003; 64:1564.
  13. Palacín M, Nunes V, Font-Llitjós M, et al. The genetics of heteromeric amino acid transporters. Physiology (Bethesda) 2005; 20:112.
  14. Bartoccioni P, Rius M, Zorzano A, et al. Distinct classes of trafficking rBAT mutants cause the type I cystinuria phenotype. Hum Mol Genet 2008; 17:1845.
  15. Goodyer P, Saadi I, Ong P, et al. Cystinuria subtype and the risk of nephrolithiasis. Kidney Int 1998; 54:56.
  16. Font-Llitjós M, Jiménez-Vidal M, Bisceglia L, et al. New insights into cystinuria: 40 new mutations, genotype-phenotype correlation, and digenic inheritance causing partial phenotype. J Med Genet 2005; 42:58.
  17. Horsford J, Saadi I, Raelson J, et al. Molecular genetics of cystinuria in French Canadians: identification of four novel mutations in type I patients. Kidney Int 1996; 49:1401.
  18. Wartenfeld R, Golomb E, Katz G, et al. Molecular analysis of cystinuria in Libyan Jews: exclusion of the SLC3A1 gene and mapping of a new locus on 19q. Am J Hum Genet 1997; 60:617.
  19. Chillarón J, Roca R, Valencia A, et al. Heteromeric amino acid transporters: biochemistry, genetics, and physiology. Am J Physiol Renal Physiol 2001; 281:F995.
  20. Pineda M, Font M, Bassi MT, et al. The amino acid transporter asc-1 is not involved in cystinuria. Kidney Int 2004; 66:1453.
  21. Parvari R, Hershkovitz E. Chromosomal microdeletions and genes' functions: a cluster of chromosomal microdeletions and the deleted genes' functions. Eur J Hum Genet 2007; 15:997.
  22. Lambert EH, Asplin JR, Herrell SD, Miller NL. Analysis of 24-hour urine parameters as it relates to age of onset of cystine stone formation. J Endourol 2010; 24:1179.
  23. Cranidis AI, Karayannis AA, Delakas DS, et al. Cystine stones: the efficacy of percutaneous and shock wave lithotripsy. Urol Int 1996; 56:180.
  24. Worcester EM, Parks JH, Evan AP, Coe FL. Renal function in patients with nephrolithiasis. J Urol 2006; 176:600.
  25. Evan AP, Coe FL, Lingeman JE, et al. Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int 2006; 69:2227.
  26. Finocchiaro R, D'Eufemia P, Celli M, et al. Usefulness of cyanide-nitroprusside test in detecting incomplete recessive heterozygotes for cystinuria: a standardized dilution procedure. Urol Res 1998; 26:401.
  27. Nakagawa Y, Coe FL. A modified cyanide-nitroprusside method for quantifying urinary cystine concentration that corrects for creatinine interference. Clin Chim Acta 1999; 289:57.
  28. Giugliani R, Ferrari I, Greene LJ. An evaluation of four methods for the detection of heterozygous cystinuria. Clin Chim Acta 1987; 164:227.
  29. Nakagawa Y, Asplin JR, Goldfarb DS, et al. Clinical use of cystine supersaturation measurements. J Urol 2000; 164:1481.
  30. Botzenhart E, Vester U, Schmidt C, et al. Cystinuria in children: distribution and frequencies of mutations in the SLC3A1 and SLC7A9 genes. Kidney Int 2002; 62:1136.
  31. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327:1141.
  32. van Hoeve K, Vermeersch P, Regal L, Levtchenko E. Necessity of fractionated urine collection for monitoring patients with cystinuria. Clin Chem 2011; 57:780.
  33. Pak CY, Fuller CJ. Assessment of cystine solubility in urine and of heterogeneous nucleation. J Urol 1983; 129:1066.
  34. Tiselius HG. New horizons in the management of patients with cystinuria. Curr Opin Urol 2010; 20:169.
  35. Singer A, Das S. Cystinuria: a review of the pathophysiology and management. J Urol 1989; 142:669.
  36. Rogers A, Kalakish S, Desai RA, Assimos DG. Management of cystinuria. Urol Clin North Am 2007; 34:347.
  37. Jaeger P, Portmann L, Saunders A, et al. Anticystinuric effects of glutamine and of dietary sodium restriction. N Engl J Med 1986; 315:1120.
  38. Goldfarb DS, Coe FL, Asplin JR. Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int 2006; 69:1041.
  39. Sterrett SP, Penniston KL, Wolf JS Jr, Nakada SY. Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Urology 2008; 72:278.
  40. Ahlstrand C, Tiselius HG. Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol 1987; 21:225.
  41. Barbey F, Nseir G, Ferrier C, et al. [Carbonic anhydrase inhibitors and calcium phosphate stones]. Nephrologie 2004; 25:169.
  42. Barbey F, Joly D, Rieu P, et al. Medical treatment of cystinuria: critical reappraisal of long-term results. J Urol 2000; 163:1419.
  43. Asplin DM, Asplin JR. The Interaction of thiol drugs and urine pH in the treatment of cystinuria. J Urol 2013; 189:2147.
  44. Hall CL, Jawad S, Harrison PR, et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. Br Med J (Clin Res Ed) 1988; 296:1083.
  45. Habib GS, Saliba W, Nashashibi M, Armali Z. Penicillamine and nephrotic syndrome. Eur J Intern Med 2006; 17:343.
  46. Ntoso KA, Tomaszewski JE, Jimenez SA, Neilson EG. Penicillamine-induced rapidly progressive glomerulonephritis in patients with progressive systemic sclerosis: successful treatment of two patients and a review of the literature. Am J Kidney Dis 1986; 8:159.
  47. DeBerardinis RJ, Coughlin CR 2nd, Kaplan P. Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children. J Urol 2008; 180:2620.
  48. Knoll T, Zöllner A, Wendt-Nordahl G, et al. Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr Nephrol 2005; 20:19.
  49. Pak CY, Fuller C, Sakhaee K, et al. Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol 1986; 136:1003.
  50. Lindell A, Denneberg T, Hellgren E, et al. Clinical course and cystine stone formation during tiopronin treatment. Urol Res 1995; 23:111.
  51. Tasic V, Lozanovski VJ, Ristoska-Bojkovska N, et al. Nephrotic syndrome occurring during tiopronin treatment for cystinuria. Eur J Pediatr 2011; 170:247.
  52. Purohit RS, Stoller ML. Stone clustering of patients with cystine urinary stone formation. Urology 2004; 63:630.
  53. Mårtensson J, Denneberg T, Lindell A, Textorius O. Sulfur amino acid metabolism in cystinuria: a biochemical and clinical study of patients. Kidney Int 1990; 37:143.
  54. Lindell A, Denneberg T, Eneström S, et al. Membranous glomerulonephritis induced by 2-mercaptopropionylglycine (2-MPG). Clin Nephrol 1990; 34:108.
  55. Sloand JA, Izzo JL Jr. Captopril reduces urinary cystine excretion in cystinuria. Arch Intern Med 1987; 147:1409.
  56. Perazella MA, Buller GK. Successful treatment of cystinuria with captopril. Am J Kidney Dis 1993; 21:504.
  57. Parvex P, Rozen R, Dziarmaga A, Goodyer P. Studies of urinary cystine precipitation in vitro: ontogeny of cystine nephrolithiasis and identification of meso-2,3-dimercaptosuccinic acid as a potential therapy for cystinuria. Mol Genet Metab 2003; 80:419.
  58. Pareek G, Steele TH, Nakada SY. Urological intervention in patients with cystinuria is decreased with medical compliance. J Urol 2005; 174:2250.
  59. Worcester EM, Coe FL, Evan AP, Parks JH. Reduced renal function and benefits of treatment in cystinuria vs other forms of nephrolithiasis. BJU Int 2006; 97:1285.
  60. Chow GK, Streem SB. Medical treatment of cystinuria: results of contemporary clinical practice. J Urol 1996; 156:1576.
  61. Pietrow P, Auge BK, Weizer AZ, et al. Durability of the medical management of cystinuria. J Urol 2003; 169:68.
  62. Fjellstedt E, Denneberg T, Jeppsson JO, et al. Cystine analyses of separate day and night urine as a basis for the management of patients with homozygous cystinuria. Urol Res 2001; 29:303.
  63. Coe FL, Clark C, Parks JH, Asplin JR. Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J Urol 2001; 166:688.
  64. Knoll LD, Segura JW, Patterson DE, et al. Long-term followup in patients with cystine urinary calculi treated by percutaneous ultrasonic lithotripsy. J Urol 1988; 140:246.
  65. Segura JW. Surgical management of urinary calculi. Semin Nephrol 1990; 10:53.
  66. Kachel TA, Vijan SR, Dretler SP. Endourological experience with cystine calculi and a treatment algorithm. J Urol 1991; 145:25.
  67. Chow GK, Streem SB. Contemporary urological intervention for cystinuric patients: immediate and long-term impact and implications. J Urol 1998; 160:341.
  68. Shekarriz B, Stoller ML. Cystinuria and other noncalcareous calculi. Endocrinol Metab Clin North Am 2002; 31:951.
  69. Sakhaee K, Poindexter JR, Pak CY. The spectrum of metabolic abnormalities in patients with cystine nephrolithiasis. J Urol 1989; 141:819.
  70. Chaudhuri TK, Paul S. Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J 2006; 273:1331.
  71. Rimer JD, An Z, Zhu Z, et al. Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design. Science 2010; 330:337.
  72. Tuso P, Barnett M, Yasunaga C, Nortman D. Cystinuria and renal transplantation. Nephron 1993; 63:478.